These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18435965)

  • 21. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results in 66 patients with reference to myocardial contrast echocardiography].
    Faber L; Seggewiss H; Fassbender D; Bogunovic N; Strick S; Schmidt HK; Gleichmann U
    Z Kardiol; 1998 Mar; 87(3):191-201. PubMed ID: 9586154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients.
    Guo H; Wang J; Chen J; Shan J; Lee JD; Ueda T
    Can J Cardiol; 2004 Jun; 20(8):779-82. PubMed ID: 15229758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy].
    Qiao SB; Gao RL; You SJ; Yuan JS; Chen JL; Yang YJ
    Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):210-2. PubMed ID: 16624154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation.
    van der Lee C; Scholzel B; ten Berg JM; Geleijnse ML; Idzerda HH; van Domburg RT; Vletter WB; Serruys PW; ten Cate FJ
    Am J Cardiol; 2008 May; 101(9):1315-20. PubMed ID: 18435964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy.
    Tsuchikane E; Takeda Y; Kobayashi T; Yachiku K; Nasu K; Kobayashi Y; Matsumoto H; Awata N
    Circ J; 2003 Sep; 67(9):763-7. PubMed ID: 12939552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myocardial perfusion after percutaneous transluminal septal myocardial ablation as assessed by myocardial contrast echocardiography in patients with hypertrophic obstructive cardiomyopathy.
    Pedone C; Biagini E; Galema TW; Vletter WB; ten Cate FJ
    J Am Soc Echocardiogr; 2006 Aug; 19(8):982-6. PubMed ID: 16880092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic resonance imaging of microvascular obstruction in hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation.
    Amano Y; Kitamura M; Yamada F; Aita K; Takayama M; Tachi M; Kumita S
    Acta Radiol; 2015 Nov; 56(11):1323-8. PubMed ID: 25414371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of alcohol septal ablation on left ventricular diastolic filling patterns in obstructive hypertrophic cardiomyopathy.
    Chen YZ; Duan FJ; Yuan JS; Hu FH; Cui JG; Yang WX; Zhang Y; Wang H; Qiao SB
    Heart Vessels; 2016 May; 31(5):744-51. PubMed ID: 25739657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation.
    Malek LA; Chojnowska L; Klopotowski M; Maczynska R; Demkow M; Witkowski A; Kusmierczyk B; Piotrowicz E; Konka M; Dabrowski M; Ruzyllo W
    Eur J Heart Fail; 2008 Nov; 10(11):1123-6. PubMed ID: 18840395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Left ventricular systolic function following alcohol septal ablation for symptomatic hypertrophic cardiomyopathy.
    Moss TJ; Krantz MJ; Zipse MM; Quaife RA; Sauer WH; Messenger JC; Groves BM; Salcedo EE; Schuller JL
    Am J Cardiol; 2014 Apr; 113(8):1401-4. PubMed ID: 24576545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The biphasic course of changes of left ventricular outflow gradient after alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
    Veselka J; Duchonová R; Procházková S; Homolová I; Pálenícková J; Zemánek D; Pernisová Z; Tesar D
    Kardiol Pol; 2004 Feb; 60(2):133-6; discussion 137. PubMed ID: 15116158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regional difference of microcirculation in patients with asymmetric hypertrophic cardiomyopathy: transthoracic Doppler coronary flow velocity reserve analysis.
    Tesic M; Djordjevic-Dikic A; Beleslin B; Trifunovic D; Giga V; Marinkovic J; Petrovic O; Petrovic M; Stepanovic J; Dobric M; Vukcevic V; Stankovic G; Seferovic P; Ostojic M; Vujisic-Tesic B
    J Am Soc Echocardiogr; 2013 Jul; 26(7):775-82. PubMed ID: 23643850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of left ventricular myocardial perfusion and function using gated SPECT in patients with hypertrophic obstruction cardiomyopathy following percutaneous transluminal septal myocardial ablation.
    Zhang L; Liu R; Qiao SB; Sun XX; He ZX; Tian YQ
    Nucl Med Commun; 2014 Jul; 35(7):762-6. PubMed ID: 24681766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Right ventricular energetics in patients with hypertrophic cardiomyopathy and the effect of alcohol septal ablation.
    Timmer SA; Knaapen P; Germans T; Lubberink M; Dijkmans PA; Vonk-Noordegraaf A; Ten Berg JM; Ten Cate FJ; Lammertsma AA; van Rossum AC
    J Card Fail; 2011 Oct; 17(10):827-31. PubMed ID: 21962421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets.
    van der Lee C; ten Cate FJ; Geleijnse ML; Kofflard MJ; Pedone C; van Herwerden LA; Biagini E; Vletter WB; Serruys PW
    Circulation; 2005 Jul; 112(4):482-8. PubMed ID: 16027255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy.
    Flores-Ramirez R; Lakkis NM; Middleton KJ; Killip D; Spencer WH; Nagueh SF
    J Am Coll Cardiol; 2001 Jan; 37(1):208-14. PubMed ID: 11153740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Percutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy: immediately and middle-term follow-up results].
    Jiang T; Wu X; Jia C
    Zhonghua Nei Ke Za Zhi; 2001 Oct; 40(10):663-5. PubMed ID: 11769718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myocardial perfusion improvement and mechanism after percutaneous intramyocardial septal radiofrequency ablation in obstructive hypertrophic cardiomyopathy: a study of myocardial contrast echocardiography.
    Yao L; Ta S; Wang J; Han C; Lei C; Li W; Li J; Wang B; Zhao X; Liu L
    Int J Cardiovasc Imaging; 2024 Jul; 40(7):1483-1492. PubMed ID: 38709352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Left ventricular endocardial pacing predicts the reduction of left ventricular outflow tract pressure gradient immediately after percutaneous transseptal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy refractory to medication.
    Chen SL; Dai ZL; Li ZQ; Hu ZY; Ye F; Zhang JJ; Zhang FF; Luo J; Zhu ZS; Lin S; Wu CQ; Tian NL
    Chin Med J (Engl); 2007 Apr; 120(7):562-8. PubMed ID: 17442203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Percutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy.
    Jiang T; Wu X; Jia C; Zhang Y; Lü Q
    Chin Med J (Engl); 2002 Jan; 115(1):26-30. PubMed ID: 11930652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.